- $759.35m
- -$146.00m
- $74.21m
- 69
- 26
- 55
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 0.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.9% | ||
| Return on Equity | -38.09% | ||
| Operating Margin | -791.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 76.37 | 1,095.41 | 1,615.8 | 86.18 | 74.2 | 27.03 | 31.82 | 55.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -3.41 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Directors
- Vicki Sato NEC (72)
- George Scangos PRE (73)
- Howard Horn CFO (43)
- Herbert Virgin EVP (65)
- Ann Hanly CTO (51)
- Steven Rice CAD (61)
- Phil Pang OTH (46)
- Jeffrey Hatfield IND (63)
- Robert More IND (53)
- Janet Napolitano IND (63)
- Robert Nelsen IND (58)
- Dipchand Nishar IND (52)
- Robert Perez IND
- Saira Ramasastry IND (45)
- Phillip Sharp IND (76)
- Elliott Sigal IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 7th, 2016
- Public Since
- October 11th, 2019
- No. of Employees
- 408
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 138,063,698
- Address
- 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, 94158
- Web
- https://www.vir.bio/
- Phone
- +1 4159064324
- Auditors
- Ernst & Young LLP
Upcoming Events for VIR
Vir Biotechnology Inc Annual Shareholders Meeting
Vir Biotechnology Inc Annual Shareholders Meeting
Q2 2025 Vir Biotechnology Inc Earnings Release
Similar to VIR
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Vir Biotechnology share price?
As of Today at 23:59 UTC, shares in Vir Biotechnology are trading at $5.50. This share price information is delayed by 15 minutes.
How has the Vir Biotechnology share price performed this year?
Shares in Vir Biotechnology last closed at $5.50 and the price had moved by -33.33% over the past 365 days. In terms of relative price strength the Vir Biotechnology share price has underperformed the S&P500 Index by -37.31% over the past year.
What are the analyst and broker recommendations for Vir Biotechnology?
The overall consensus recommendation for Vir Biotechnology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vir Biotechnology dividend yield?
Vir Biotechnology does not currently pay a dividend.
Does Vir Biotechnology pay a dividend?
Vir Biotechnology does not currently pay a dividend.
When does Vir Biotechnology next pay dividends?
Vir Biotechnology does not currently pay a dividend.
How do I buy Vir Biotechnology shares?
To buy shares in Vir Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vir Biotechnology?
As of the previous close price of $5.50, shares in Vir Biotechnology had a market capitalisation of $759.35m.
Where are Vir Biotechnology shares listed?
Here are the trading details for Vir Biotechnology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: VIR
What kind of share is Vir Biotechnology?
Based on an overall assessment of its quality, value and momentum Vir Biotechnology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vir Biotechnology share price forecast for 2025?
The analyst consensus target price for shares in Vir Biotechnology is $33.57. That is 510.36% above the last closing price of $5.50.
Analysts covering Vir Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of -$3.36 for the next financial year.
Find out moreWhat is the trend in the Vir Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vir Biotechnology. Over the past six months, its share price has underperformed the S&P500 Index by -20.12%.
As of the last closing price of $5.50, shares in Vir Biotechnology were trading -33.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vir Biotechnology PE Ratio?
The Vir Biotechnology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vir Biotechnology?
Vir Biotechnology's management team is headed by:
- Vicki Sato - NEC
- George Scangos - PRE
- Howard Horn - CFO
- Herbert Virgin - EVP
- Ann Hanly - CTO
- Steven Rice - CAD
- Phil Pang - OTH
- Jeffrey Hatfield - IND
- Robert More - IND
- Janet Napolitano - IND
- Robert Nelsen - IND
- Dipchand Nishar - IND
- Robert Perez - IND
- Saira Ramasastry - IND
- Phillip Sharp - IND
- Elliott Sigal - IND